Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics
Status:
Completed
Trial end date:
2019-05-22
Target enrollment:
Participant gender:
Summary
Single centre, open-label, random order, cross-over trial, recruited over a period of
approximately 2 years. Sufficient participants enrolled to complete 16 adults. Withdrawn
subjects may be replaced.
This clinical trial will assess the effects of ultra-long acting bronchodilator therapy in
smoking asthmatics taking inhaled corticosteroids. This will be via a pulmonary function test
called impulse oscillometry.